Leuko

Executive Summary

Leuko is a Spanish digital health company developing PointCheck™, a first-in-class non-invasive device for real-time monitoring of white blood cell (WBC) levels using light and AI. By imaging blood cells in fingernail capillaries, the device aims to empower immunosuppressed patients—especially those undergoing chemotherapy—to detect neutropenia early and avoid severe infections. The solution addresses a critical gap in oncology care, where frequent blood draws are burdensome and delays in infection detection can be life-threatening. Currently investigational and not yet approved by the FDA or CE, Leuko has raised undisclosed funding and is advancing through clinical validation. If successful, PointCheck could become a standard home-monitoring tool for millions of cancer patients globally, reducing hospitalization and improving quality of life. The company was founded in 2017 and is headquartered in Barcelona.

Upcoming Catalysts (preview)

• Q1 2025Initiation of FDA or CE pivotal clinical trial40% success
• Q3 2025Regulatory submission (CE mark or FDA 510(k))30% success
• TBDStrategic partnership with oncology or diagnostics company50% success